Salmeterol enhances pulmonary fibrinolysis in healthy volunteers
Authors:
- Alex F. de VosAVAlex F. de Vos
- Paul BresserPBPaul Bresser
- Jaring S. van der ZeeJZJaring S. van der Zee
- Henk M. JansenHJHenk M. Jansen
- Marcel LeviMLMarcel Levi
- Tom van der PollTPTom van der Poll
- 1 January 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 35 (1) , 57-63
Abstract
Various lung diseases are associated with local activation of coagulation and concurrent inhibition of fibrinolysis. Although salmeterol, a β2-adrenoceptor agonist with profound bronchodilatory properties, has been studied extensively, the effects of this compound on the pulmonary hemostatic balance are not elucidated. A single-blinded, placebo-controlled study. University hospital and laboratory. A total of 32 human volunteers. Subjects inhaled 100 μg of salmeterol or placebo (t = −30 mins) followed by 100 μg of lipopolysaccharide (LPS) or normal saline (t = 0 mins; n = 8 per group). Measurements were performed in bronchoalveolar lavage fluid obtained 6 hrs postchallenge. Inhalation of LPS enhanced pulmonary coagulation as determined by an increase in the concentrations of thrombin–antithrombin complexes, factor VIIa, and soluble tissue factor in bronchoalveolar lavage fluid (all p < .05 vs. saline). LPS concurrently inhibited pulmonary fibrinolysis, as reflected by a decrease in bronchoalveolar lavage fluid plasminogen activator activity together with an increase in plasminogen activator inhibitor type 1 (both p < .05 vs. saline). Moreover, LPS inhalation was associated with a suppression of the anticoagulant protein C pathway, as indicated by an increase in soluble thrombomodulin and decreases in protein C and activated protein C levels in bronchoalveolar lavage fluid (all p < .05 vs. saline). Salmeterol, either with or without LPS inhalation, enhanced fibrinolysis (plasminogen activator activity and tissue-type and urokinase-type plasminogen activator levels) but did not influence LPS-induced changes in coagulation or the protein C pathway. Salmeterol has profibrinolytic properties in the normal lung and when applied in a model of sterile pulmonary inflammation.Keywords
This publication has 42 references indexed in Scilit:
- Activated Protein C Inhibits Local Coagulation after Intrapulmonary Delivery of Endotoxin in HumansAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteersThrombosis and Haemostasis, 2005
- Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharideBlood, 2004
- Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumoniaThorax, 2004
- Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin applicationThrombosis and Haemostasis, 2004
- Extrinsic Coagulation Blockade Attenuates Lung Injury and Proinflammatory Cytokine Release after Intratracheal LipopolysaccharideAmerican Journal of Respiratory Cell and Molecular Biology, 2002
- Coagulation Blockade Prevents Sepsis-induced Respiratory and Renal Failure in BaboonsAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe Pneumonia: Comparison with the Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Thrombin in the Airways of Asthmatic PatientsLung, 1999
- Local activation of the coagulation and fibrinolysis systems in lung diseaseThrombosis Research, 1990